Alnylam Pharmaceuticals Inc to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss results from ENVISION Phase III study on givosiran.
(Operator Instructions) Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.
Good morning. I'm Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam.
With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Barry Greene, our President. Also joining us in the room and available for Q&A is Akin Akinc, general manager of the givosiran program.
For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the investor page of our website, www.alnylam.com.
Now turning
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |